We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.15% | 149.70 | 149.89 | 147.82 | 149.89 | 6,532,721 | 00:38:06 |
From Nov 2023 to May 2024
By Ben Glickman
Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal.
The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx for $28 each was expected have a value of $1.9 billion net of estimated cash required.
Ambrx said the deal represented a premium of 105% on the Jan. 5 closing price.
Ambryx is currently developing candidates for treatments for multiple types of cancer, including for metastatic castration-resistant prostate cancer, metastatic breast cancer and renal cell carcinoma.
Johnson & Johnson said the deal presented an opportunity to "design, develop and commercialize targeted oncology therapeutics."
The acquisition is expected to close in the first half of the year, subject to approval by Ambrx shareholders.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 08, 2024 07:57 ET (12:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
